<DOC>
	<DOCNO>NCT00474058</DOCNO>
	<brief_summary>The objective trial ass effect transdermal rotigotine control early morning motor function sleep disorder compare placebo subject idiopathic Parkinsons´s disease . In addition , effect rotigotine specific nocturnal non-motor symptom Parkinson´s disease evaluate .</brief_summary>
	<brief_title>Randomized Evaluation 24-Hour Coverage : Efficacy Rotigotine</brief_title>
	<detailed_description>The objective trial ass effect rotigotine control early morning motor function sleep disorder compare placebo subject idiopathic Parkinsons´s disease . In addition , effect rotigotine specific nocturnal non-motor symptom Parkinson´s disease evaluate . After Screening Period 28 day subject hospitalize two night . After second overnight stay , subject randomly assign either rotigotine patch placebo patch . Afterwards patient titrate optimal dose . After subject reach optimal dose ( high dose ) maintain dose certain period . At end maintenance subject hospitalize two night . Afterwards dose continuously decrease . Efficacy assess application sleep quality score , motor examination score , score evaluate non-motor symptom Parkinsons . Safety assessment include adverse event , 12-lead electrocardiogram , blood pressure heart rate assessment , laboratory check .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Early advanced Idiopathic Parkinson Disease early morning motor impairment Atypical Parkinsonian syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>rotigotine</keyword>
	<keyword>Neupro®</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>